Diabetes mellitus: Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan - 2012 version

Journal of Atherosclerosis and Thrombosis

Volumn 21, Issue 2, 2014, Pages 93-98

  Teramoto, Tamio ^a   Sasaki, Jun ^a   Ishibashi, Shun ^a   Birou, Sadatoshi ^a   Daida, Hiroyuki ^a   Dohi, Seitaro ^a   Egusa, Genshi ^a   Hiro, Takafumi ^a   Hirobe, Kazuhiko ^a   Iida, Mami ^a   Kihara, Shinji ^a   Kinoshita, Makoto ^a   Maruyama, Chizuko ^a   Ohta, Takao ^a   Okamura, Tomonori ^a   Yamashita, Shizuya ^a   Yokode, Masayuki ^a   Yokote, Koutaro ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE HEART INFARCTION; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; JAPAN; METABOLIC SYNDROME X; PHYSICAL ACTIVITY; PRACTICE GUIDELINE;

ATHEROSCLEROSIS; DIABETES MELLITUS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RESEARCH REPORT; SOCIETIES, MEDICAL; TIME FACTORS;

EID: 84894638740     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.19349     Document Type: Article

References (76)

1. Kannel WB, Mcgee DL: Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham study. Diabetes Care, 1979; 2: 120-126.
2. Vaccaro O, Stamler J, Neaton JD: Sixteen-year coronary mortality in black and white men with diabetes screened for the Multiple Risk Factor Intervention Trial (MRFIT). Int J Epidemiol, 1998; 27: 636-641.
3. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998; 339: 229-234.
4. The Emerging Risk Factors Collaboration: Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet, 2010; 375: 2215-2222.
5. Ueshima H (editor): Cardiovascular evidence from NIPPON DATA. Japan Medical Journal, 2008.
6. Fujishima M, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, Yoshitake T: Diabetes and cardiovascular disease in a prospective population survey in Japan. The Hisayama study. Diabetes, 1996; 45 (Suppl 3): S14-S16.
7. Yokoyama H, Matsushima M, Kawai K, Hirao K, Oishi M, Sugimoto H, Takeda H, Minami M, Kobayashi M, Sone H: Low incidence of cardiovascular events in Japanese patients with Type 2 diabetes in primary care settings: a prospective cohort study (JDDM 20). Diabet Med, 2011; 28: 1221-1228.
8. Sone H, Tanaka S, Tanaka S, Iimuro S, Oida K, Yamasaki Y, Oikawa S, Ishibashi S, Katayama S, Ohashi Y, Akanuma Y, Yamada N; Japan Diabetes Complicatios Study Group: Serum levels of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with Type 2 diabetes: Subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrin Metab, 2011; 96: 3448-3456.
9. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W, Bingley PJ, Patterson CC: Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia, 2003; 46: 760-765.
10. Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KYZ, Kinder LS, Ellis D, Becker DJ: Insulin resistancerelated factors, but not glycemia, predict coronary artery disease in type 1 diabetes. 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications study. Diabetes Care, 2003; 26: 1374-1379.
11. Nesto RW, Phillips RT, Kett KG, Hill T, Perper E, Young E, Leland OS: Angina and exertional myocardial ischemia in diabetic and nondiabetic patients: Assessment by exercise thallium scintigraphy. Ann Intern Med, 1988; 108: 170-175.
12. Goraya TY, Leibson CL, Palumbo PJ, Weston SA, Killian JM, Pfeifer EA, Jacobsen SJ, Frye RL, Roger VL: Coronary atherosclerosis in diabetes mellitus. A population based autopsy study. J Am Coll Cardiol, 2002; 40: 946-953.
13. Ledru F, Ducimetiere P, Battaglia S, Courbon D, Beverelli F, Guize L, Guermonprez JL, Diebold B: New diagnostic criteria for diabetes and coronary artery disease: Insights from an angiographic study. J Am Coll Cardiol, 2001; 37: 1543-1550.
14. Hoff JA, Quinn L, Sevrukov A, Lipton RB, Daviglus M, Garside DB, Ajmere NK, Gandhi S, Kondos GT: The prevalence of coronary artery calcium among diabetic individuals without known coronary artery disease. J Am Coll Cardiol, 2003; 41: 1008-1012.
15. Iso H, Imano H, Kitamura A, Sato S, Naito Y, Tanigawa T, Ohira T, Yamagishi K, Iida M, Shimamoto T: Type 2 diabetes and risk of non-embolic ischaemic stroke in Japanese men and women. Diabetologia, 2004; 47: 2137-2144.
16. Kobayashi S: The Japanese stroke databank 2009. Nakayama Shoten, 2009; 78-79.
17. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM: Diabetes and mortality following acute coronary syndromes. JAMA, 2007; 298: 765-775.
18. Takara A, Ogawa H, Endoh Y, Mori F, Yamaguchi J, Takagi A, Koyanagi R, Shiga T, Kasanuki H, Hagiwara N: Long-term prognosis of diabetic patients with acute myocardial infarction in the era of acute revascularization. Cardiovascular Diabetology, 2010; 366: 9: 1-7.
19. Kasai T, Miyauchi K, Kajimoto K, Kubota N, Kurata T, Daida H: Influence of diabetes on >10-year outcomes after percutaneous coronary intervention. Heart Vessels, 2008; 23: 149-154.
20. Hillen T, Coshall C, Tilling K, Rudd AG, McGovern R, Wolfe CDA: Cause of stroke recurrence is multifactorial patterns: risk factors and outcomes of stroke recurrence in the south London stroke register. Stroke, 2003; 34: 1457-1463.
21. Shinohara Y, Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohashi Y: Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis, 2008; 26: 63-70.
22. Murabito JM, Agostino RBD, Silbershatz H, Wilson PWF: Intermittent claudication. A risk profile from the Framingham heart study. Circulation, 1997; 96: 44-49.
23. Huxley R, Barzi F, Woodward M: Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ, 2006; 322: 73-78.
24. Doi Y, Ninomiya T, Hata J, Fukuhara M, Yonemoto K, Iwase M, Iida M, Kiyohara Y: Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population. The Hisayama study. Stroke, 2010; 41: 203-209.
25. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H: Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet, 1980; 1: 1373-1376.
26. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata diabetes study. Diabetes Care, 1999; 22: 920-924.
27. DECODE study group, the European Diabetes Epidemiology Group: Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med, 2001; 161: 397-405.
28. Nakagami T; DECODA Study Group: Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia, 2004; 47: 385-394.
29. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ, 1998; 316: 823-828.
30. Murakami K, Ishibashi S, Yamada N, Akanuma Y: Lipoprotein(a) as a coronary risk factor in Japanese patients with Type II (non-insulin-dependent) diabetes mellitus. Relation with apolipoprotein(a) phenotypes. Diabetologia, 1998; 41: 1397-1399.
31. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallè JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA, 2001; 286: 421-426.
32. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS Group: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int, 2003; 63: 225-232.
33. Cheung N, Wang JJ, Klein R, Couper DJ, Sharrett AR, Wong TY: Diabetic retinopathy and the risk of coronary heart disease. The atherosclerosis risk in communities study. Diabetes Care, 2007; 30: 1742-1746.
34. Davis TME, Millns H, Stratton IM, Holman RR, Turner RC: Risk factors for stroke in type 2 diabetes mellitus. United Kingdom Prospective Diabetes Study (UKPDS 29). Arch Intern Med, 1999; 159: 1097-1103.
35. Ciccarone E, Castelnuovo AD, Assanelli D, Archetti S, Ruggeri G, Salcuni N, Donati MB, Capani F, Iacoviello L: Homocysteine levels are associated with the severity of peripheral arterial disease in Type 2 diabetic patients. J Thromb Haemost, 2003; 1: 2540-2547.
36. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 2003; 348: 383-393.
37. Gæde P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med, 2008; 358: 580-591.
38. Araki S, Haneda M, Koya D, Hidaka H, Sugimoto T, Isono M, Isshiki K, Chin-Kanasaki M, Uzu T, Kashiwagi A: Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes, 2007; 56: 1727-1730.
39. Berardis DG, Sacco M, Strippoli GFM, Pellegrini F, Graziano G, Tognoni G, Nicolucci A: Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ, 2009; 339: b4531.
40. Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, Bosch J, Dagenais G, Mann JFE, Gerstein HC: Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes. Results of the HOPE study and MICRO-HOPE study. Diabetes Care, 2002; 25: 1919-1927.
41. Iso H, Date C, Yamamoto A, Toyoshima H, Wtanabe Y, Kikuchi S, Koizumi A, Wada Y, Kondo T, Inaba Y, Tamacoshi A: Smoking cessation and mortality from cardiovascular disease among Japanese men and women: the JACC Study. Am J Epidemiol, 2005; 161: 170-179.
42. Kuller LH, Ockene JK, Meilahn E, Wentworth DN, Svendsen KH, Neaton JD: Cigarette smoking and mortality. MRFIT research group. Prev Med, 1991; 20: 638-654.
43. Manson JE, Greenland P, LaCroix AZ, Stefanick ML, Mouton CP, Oberman A, Perri MG, Sheps DS, Pettinger MB, Siscovick DS: Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med, 2002; 347: 716-725.
44. Noda H, Iso H, Toyoshima H, Date C, Yamamoto A, kikuchi S, Koizumi A, Kondo T, Watanabe Y, Wada Y, Inaba Y, Tamakoshi A: Walking and sports participation and mortality from coronary heart disease and stroke. J Am Coll Cardiol, 2005; 46: 1761-1767.
45. Ornish D, Scherwitz LW, Billings JH, Gould KL, Merritt TA, Sparler S, Armstrong WT, Ports TA, Kirkeeide RL, Hogeboom C, Brand RJ: Intensive lifestyle changes for reversal of coronary heart disease. JAMA, 1998; 280: 2001-2007.
46. Angermayr L, Melchart D, Linde K: Multifactorial lifestyle interventions in the primary and secondary prevention of cardiovascular disease and type 2 diabetes mellitusa systematic review of randomized controlled trials. Ann Behav Med, 2010; 40: 49-64.
47. Pi-Sunyer FX, Maggio CA, McCarron DA, Reusser ME, Stern JS, Haynes RB, Oparil S, Kris-Etherton P, Resnick LM, Chait A, Morris CD, Hatton DC, Metz JA, Snyder GW, Clark S, McMahon M: Multicenter randomized trial of a comprehensive prepared meal program in type 2 diabetes. Diabetes Care, 1999; 22: 191-197.
48. Pastors JG, Franz M, Warshaw H, Kulkarni K, Daly A: The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care, 2002; 25: 608-613.
49. Thomas D, Elliott EJ, Naughton GA: Exercise for type 2 diabetes mellitus (Review). Cochrane Database Syst Rev, 2006; CD002968.
50. Al-Delaimy WK, Manson JE, Solomon CG, Kawachi I, Stampfer MJ, Willett WC, Hu FB: Smoking and risk of coronary heart disease among women with type 2 diabetes mellitus. Arch Intern Med, 2002; 162: 273-279.
51. Hu FB, Stampfer MJ, Solomon C, Liu S, Colditz GA, Speizer FE, Willett WC, Manson JE: Physical activity and risk for cardiovascular events in diabetic women. Ann Intern Med, 2001; 134: 96-105.
52. Heart Protection Study Collaborating Group: Heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet, 2003; 361: 2005-2016.
53. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, Thomasan MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004; 364: 685.
54. Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy of cholesterol-lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: a metaanalysis. Lancet, 2008; 371: 117-125.
55. FIELD study investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 2005; 366: 1849-1861.
56. Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008; 358: 2545-2559.
57. ACCORD Study Group: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med, 2010; 362: 1563-1574.
58. Oikawa S, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K: Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA lipid intervention study (JELIS). Atherosclerosis, 2009; 206: 535-539.
59. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, Zeeuw DD, Gronhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of heart and renal protection): a randomised placebo-controlled trial. Lancet, 2011; 377: 2181-2192.
60. Japan Atherosclerosis Society (JAS) (edit): Guidelines for prevention of atherosclerotic cardiovascular diseases 2007.
61. Li C, Ford ES, Tsai J, Zhao G, Balluz LS, Gidding SS: Serum non-high-density lipoprotein cholesterol concentration and risk of death from cardiovascular disease among U.S. adults with diagnosed diabetes: the third national health and nutrition examination survey linked mortality study. Cardiovasc Diabetol, 2011; 10: 46-58.
62. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 2001; 285: 2486-2497.
63. American diabetes association: Clinical practice recommendations 2011. Diabetes Care, 2011; 34 (Suppl 1): S29-S31.
64. Reiner Z, Catapano AL, Backer GD, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D: ESC/EAS 172 guidelines for the management of dyslipidemias: The task force for the management of dyslipidemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J, 2011; 32: 1769-1818.
65. Mabuchi H: J-LIT chart 1. Primary prevention of coronary artery disease in Japanese population: coronary risk factors. Domyaku Koka, 2001; 29: 296.
66. Mabuchi H: Overlap of risk factors and coronary events. The Lipid, 2007; 18: 63-72.
67. Oikawa S, Kita T, Mabuchi H, Matsuzaki M, Matsuzawa Y, Nakaya N, Saito Y, Sasaki J, Shimamoto K, Itakura H: Risk of coronary events in Japanese patients with both hypercholesterolemia and type 2 diabetes mellitus on lowdose simvastatin therapy: Implication from Japan Lipid Intervention Trial (JLIT). Atherosclerosis, 2007; 191: 440-446.
68. Kashiwagi A, Kida Y, Harada N, Kikkawa R: Macrovascular complications as risk factors for diabetic retinopathy: Microvascular and macrovascular complications. Folia ophthalmologica Japonica, 2000; 51: 7-10.
69. Yokoyama H, Oishi M, Kawai K, Sone H: Reduced GFR and microalbuminuria are independently associated with prevalent cardiovascular disease in type 2 diabetes: JDDM study 16. Diabet Med, 2008; 25: 1426-1432.
70. Ito H, Takeuchi Y, Ishida H, Antoku S, Abe M, Mifune M, Togane M: High frequencies of diabetic micro-and macroangiopathies in patients with type 2 diabetes mellitus with decreased estimated glomerular filtration rate and normoalbuminuria. Nephrol Dial Transplant, 2010; 25: 1161-1167.
71. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000; 321: 405-412.
72. Nishimura R, Nakagami T, Sone H, Ohashi Y, Tajima N: Relationship between hemoglobin A1c and cardiovascular disease in mild-to-moderate hypercholesterolemic Japanese individuals: subanalysis of a large-scale randomized controlled trial. Cardiovasc Diabetol, 2011; 10: 58-63.
73. Nakanishi S, Yamada M, Hattori N, Suzuki G: Relationship between HbA1c and mortality in a Japanese population. Diabetologia, 2005; 48: 230-234.
74. Kadota A, Hozawa A, Okamura T, Kadowaki T, Nakamura K, Murakami Y, Hayakawa T, Kita Y, Okayama A, Nakamura Y, Kashiwagi A, Ueshima H: Relationship between metabolic risk factor clustering and cardiovascular mortality stratified by high blood glucose and obesity. NIPPON DATA90, 1990-2000. Diabetes Care, 2007; 30: 1533-1538.
75. Krempf M, Parhofer KG, Steg G, Bhatt DL, Ohman EM, Röther J, Goto S, Pasquet B, Wilson PWF: Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis [from the Reduction of Atherothrombosis for Continued Health (REACH) registry]. Am J Cardiol, 2010; 105: 667-671.
76. Ninomiya T, Kubo M, Doi Y, Yonemoto K, Tanizaki Y, Rahman M, Arima H, Tsuruya K, Iida M, Kiyohara Y: Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population. The Hisayama study. Stroke, 2007; 38: 2063-2069